Publications by authors named "C Steven Ernest"

Coronavirus disease 2019 (COVID-19) has affected not only individual lives but also the world and global systems, both natural and human-made. Besides millions of deaths and environmental challenges, the rapid spread of the infection and its very high socioeconomic impact have affected healthcare, economic status and wealth, and mental health across the globe. To better appreciate the pandemic's influence, multidisciplinary and interdisciplinary approaches are needed.

View Article and Find Full Text PDF

A laser-assisted see-through technology is developed to locate sound sources inside a structure and to analyze the interior sound field. Six lasers were employed to measure simultaneously the normal velocities on the exterior surface. These input data were used to locate sound sources inside a solid structure using a passive sonic detection and ranging algorithm, and then to reconstruct the interior sound field using the Helmholtz equation least squares method, and finally to observe the changes of the interior sound field over time through computer tomography.

View Article and Find Full Text PDF
Article Synopsis
  • Donanemab is an amyloid-targeting therapy aimed at treating Alzheimer's disease by reducing brain amyloid plaques and its effects on plasma biomarkers and clinical outcomes are being analyzed.
  • In studies involving Alzheimer's patients, models were developed to evaluate the relationship between donanemab exposure, plasma biomarkers like p-tau217 and GFAP, and disease progression.
  • The results indicate that donanemab effectively decreases plasma levels of p-tau217 and GFAP and significantly slows clinical decline in patients, regardless of the severity of their disease at the start of treatment.
View Article and Find Full Text PDF
Article Synopsis
  • * The study analyzed how the drug's levels in the body relate to its ability to reduce plaques and cause imaging abnormalities, revealing that certain factors like body weight influence donanemab exposure but not its effectiveness.
  • * Maintaining a specific concentration of donanemab in the bloodstream is linked to plaque reduction, with most participants clearing amyloid plaques by 52 weeks; however, individuals with the apolipoprotein ε4 variant face a higher risk of side effects.
View Article and Find Full Text PDF

The relationship between severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) viral load reduction and disease symptom resolution remains largely undefined for coronavirus disease 2019 (COVID-19). While the vaccine-derived immunity takes time to develop, neutralizing monoclonal antibodies offer immediate, passive immunity to patients with COVID-19. Bamlanivimab and etesevimab are two potent neutralizing monoclonal antibodies directed to the receptor binding domain of the spike protein of SARS-CoV-2.

View Article and Find Full Text PDF